Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy

Table 1 Clinical and histological characteristic of hepatitis C virus patients before treatment (n = 38)

Parameters
Age (yr)	40.9 ± 14.6
Males, n (%)	20 (53)
ALT (U/L)	54 (30)
TBil (μmol/L)	11.5 (6.7)
Albumin (g/L)	45.7 ± 3.5
Platelets (× 103 μL)	173.6 ± 63.6
INR	1.00 (0.10)
HCV RNA (log IU/L)	6.24 ± 0.79
LSM, kPa	6.6 (3.6)
HCV genotype
1	23 (60)
2	3 (8)
3	12 (32)
Treatment, n (%)
SOF + RBV	17 (45)
DCV + ASV	14 (37)
GZR + EBR	7 (18)
HAI score, n (%)
0-3	6 (16)
4-6	12 (32)
7-9	9 (24)
≥ 10	11 (29)
Ishak score, n (%)
F0-2	8 (21)
F3-4	17 (45)
F5-6	13 (34)

ALT: Alanine aminotransferase; TBil: Total bilirubin; INR: International normalized ratio; HCV: Hepatitis C virus; LSM: Liver stiffness measurement; SOF + RBV: Sofosbuvir + ribavirin; DCV + ASV: Daclatasvir + asunaprevir; GZR + EBR: Grazoprevir + elbasvir; HAI: Histology activity index.